October 6, 2026 · Peptide Legal Updates
The July sentencing of the Paradigm Peptides defendants offers a concrete compliance lesson for online businesses. This October 6 analysis examines that earlier case; it does not report a new arrest or sentencing. According to the U.S. Attorney’s Office for the Northern District of Indiana, Matthew Kawa and Jennifer Stechkober were sentenced on July 30, 2026, after pleading guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead. Kawa also pleaded guilty to illegally importing merchandise.
The judgment, accurately stated
Kawa received 70 months in prison and one year of supervised release. Stechkober received 16 months in prison and one year of supervised release. The court ordered $78,317.52 in restitution and entered a $5 million money judgment against Kawa. The DOJ case page records that both defendants entered guilty pleas on December 10, 2025.
Those distinctions matter. This was not merely a search, investigation, arrest or unproven charge. The defendants pleaded guilty and were sentenced. At the same time, the punishment was tied to specific admitted conduct and case facts; it should not be presented as a rule that every peptide seller faces the same outcome.
Why the online representations mattered
DOJ said Paradigm Peptides sold peptides, SARMs, hCG and other drugs through an online business and shipped products through the mail. The government stated that the website and customer emails falsely represented that the business was FDA licensed or registered, operated its own U.S. laboratories, tested its products and sold safe, pharmaceutical-quality material. DOJ further said products were imported from countries including China and India and were not tested before sale.
The release also reports that many products labeled as SARMs were actually testosterone, a controlled substance. DOJ reported continued sales after FDA warnings in 2020 and 2022. Those facts make this case more than a dispute over an “RUO” phrase on a label.
Compliance lessons for today’s peptide businesses
First, audit every claim that can be verified against a government or third-party record. “FDA registered,” “made in the USA,” “pharmaceutical grade,” “independently tested” and similar phrases need current evidence. A marketing contractor should not be allowed to improvise regulatory status.
Second, connect certificates of analysis to actual lots and suppliers. Record the manufacturer, production location, chain of custody, test laboratory, methods, dates and any inconsistency between the invoice, package and report. A generic purity document is not a substitute for traceable quality records.
Third, treat agency correspondence as a controlled legal event. Preserve the notice, website version, advertisements, customer communications and fulfillment records. Assign responsibility, set deadlines and obtain legal and technical review. Continuing the same challenged conduct after a warning may later become important evidence about knowledge or intent.
These lessons reach beyond RUO sellers. Clinics, wellness centers, chiropractors, pharmacies and compounders should verify what vendors say about origin, testing and legal status. Influencers and affiliates should not repeat supplier claims without substantiation. Contracts should allocate access to records, regulatory-change notice, recall cooperation and responsibility for misleading representations.
Businesses that need a review of sourcing, testing claims, advertising or agency correspondence can request a confidential compliance review.
General information as of October 6, 2026; not legal advice. Reading this article or submitting information does not create an attorney-client relationship.